$ACST "Acasti told investors that a full audit of enrolling sites, including review of all raw data and records from patients taking both CaPre and placebo, will be conducted to identify a possible root cause of this 'unprecedented' placebo effect. This is likely to take at least several weeks, with an outcome expected by the end of February, it said. Notably, due to additional resources now going toward TRILOGY 1, there could be a small delay of a couple of weeks in reporting topline results for TRILOGY 2 to mid-February 2020." LOL So they take positive results out for TRILOGY 2 and then say we found anomaly for placebo. Then put their hands up and say we will do what FDA says about the NDA. Meanwhile they are buying shares at .6.